|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 155.51 USD | +2.40% |
|
+7.25% | -46.57% |
| 11-24 | US health insurers buoyed by prospect of extended Obamacare subsidies | |
| 11-24 | Health insurers rise on report Trump considering ACA subsidy extension | RE |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 7.45 | 6.2 | 7.07 | 7.43 | 6.99 | |||||
Return on Total Capital | 15.07 | 13.88 | 16.25 | 16.55 | 14.78 | |||||
Return On Equity % | 33.19 | 27.89 | 28.32 | 30.39 | 27.07 | |||||
Return on Common Equity | 33.19 | 27.89 | 28.32 | 30.39 | 27.07 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 13.9 | 12.16 | 12.62 | 13.13 | 12.09 | |||||
SG&A Margin | 7.97 | 7.54 | 7.42 | 7.45 | 7 | |||||
EBITDA Margin % | 5.56 | 4.33 | 4.85 | 5.24 | 4.66 | |||||
EBITA Margin % | 5.37 | 4.18 | 4.71 | 5.16 | 4.57 | |||||
EBIT Margin % | 5.29 | 3.99 | 4.46 | 4.9 | 4.36 | |||||
Income From Continuing Operations Margin % | 3.66 | 2.44 | 2.55 | 3.31 | 3.01 | |||||
Net Income Margin % | 3.66 | 2.44 | 2.55 | 3.31 | 3.01 | |||||
Net Avail. For Common Margin % | 3.66 | 2.44 | 2.55 | 3.31 | 3.01 | |||||
Normalized Net Income Margin | 2.96 | 2.22 | 2.57 | 2.86 | 2.54 | |||||
Levered Free Cash Flow Margin | 11.55 | 3.28 | 1.06 | 2.62 | 1.3 | |||||
Unlevered Free Cash Flow Margin | 11.89 | 3.56 | 1.28 | 2.82 | 1.49 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 2.25 | 2.48 | 2.54 | 2.43 | 2.57 | |||||
Fixed Assets Turnover | 48.87 | 69.55 | 108.55 | 198.81 | 252.67 | |||||
Receivables Turnover (Average Receivables) | - | - | - | - | - | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.59 | 1.43 | 1.47 | 1.54 | 1.62 | |||||
Quick Ratio | 1.55 | 1.39 | 1.43 | 1.49 | 1.56 | |||||
Operating Cash Flow to Current Liabilities | 0.38 | 0.3 | 0.11 | 0.2 | 0.08 | |||||
Days Sales Outstanding (Average Receivables) | - | - | - | - | - | |||||
Average Days Payable Outstanding | 64.27 | 57.43 | 57.14 | 62.19 | 60.28 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 116.41 | 96.62 | 85.39 | 59.57 | 71.71 | |||||
Total Debt / Total Capital | 53.79 | 49.14 | 46.06 | 37.33 | 41.76 | |||||
LT Debt/Equity | 114.84 | 94.71 | 83.27 | 58.6 | 70.86 | |||||
Long-Term Debt / Total Capital | 53.06 | 48.17 | 44.91 | 36.72 | 41.27 | |||||
Total Liabilities / Total Assets | 78.01 | 78.46 | 75.93 | 71.7 | 71.23 | |||||
EBIT / Interest Expense | 9.53 | 8.98 | 12.61 | 14.84 | 14.47 | |||||
EBITDA / Interest Expense | 10.29 | 10.01 | 14 | 16.02 | 15.58 | |||||
(EBITDA - Capex) / Interest Expense | 9.57 | 9.37 | 13.17 | 15.25 | 14.74 | |||||
Total Debt / EBITDA | 2.32 | 2.12 | 1.64 | 1.44 | 1.75 | |||||
Net Debt / EBITDA | -1.63 | -1.58 | -0.96 | -1.34 | -0.78 | |||||
Total Debt / (EBITDA - Capex) | 2.5 | 2.26 | 1.75 | 1.51 | 1.85 | |||||
Net Debt / (EBITDA - Capex) | -1.76 | -1.69 | -1.02 | -1.41 | -0.83 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 12.45 | 46.85 | 15.26 | 6.12 | 18.67 | |||||
Gross Profit, 1 Yr. Growth % | 4.93 | 28.38 | 19.7 | 10.39 | 9.28 | |||||
EBITDA, 1 Yr. Growth % | -7.09 | 16.1 | 33.07 | 14.86 | 5.67 | |||||
EBITA, 1 Yr. Growth % | -7.06 | 16.07 | 33.94 | 16.48 | 5.36 | |||||
EBIT, 1 Yr. Growth % | -6.9 | 12.76 | 32.85 | 16.82 | 5.82 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -8.68 | -2.08 | 20.18 | 37.75 | 8.07 | |||||
Net Income, 1 Yr. Growth % | -8.68 | -2.08 | 20.18 | 37.75 | 8.07 | |||||
Normalized Net Income, 1 Yr. Growth % | -9.09 | 12.18 | 38.2 | 18.35 | 5.65 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -2.09 | 0.18 | 20.44 | 38.52 | 8.79 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -2.11 | 8.6 | -58.17 | -3.55 | -9.82 | |||||
Accounts Receivable, 1 Yr. Growth % | - | - | - | - | - | |||||
Total Assets, 1 Yr. Growth % | 40.44 | 28.08 | 0.86 | 20.94 | 4.96 | |||||
Common Equity, 1 Yr. Growth % | 6.94 | 25.48 | 12.7 | 42.21 | 6.67 | |||||
Tangible Book Value, 1 Yr. Growth % | -38.01 | 18.12 | 14.55 | 81.54 | -8.94 | |||||
Cash From Operations, 1 Yr. Growth % | 342.62 | 11.64 | -63.52 | 115.01 | -61.25 | |||||
Capital Expenditures, 1 Yr. Growth % | 29.82 | 4.05 | 18.18 | -7.69 | 19.05 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 67.8K | -58.06 | -61.93 | 163.55 | -40.84 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 3.7K | -55.84 | -57.65 | 135.05 | -37.24 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 0.63 | 28.51 | 30.1 | 10.59 | 12.22 | |||||
Gross Profit, 2 Yr. CAGR % | -7.82 | 16.06 | 23.96 | 14.95 | 9.83 | |||||
EBITDA, 2 Yr. CAGR % | -7.25 | 3.04 | 22.84 | 24.88 | 10.19 | |||||
EBITA, 2 Yr. CAGR % | -7.44 | 3.01 | 23.17 | 26.22 | 10.8 | |||||
EBIT, 2 Yr. CAGR % | -7.3 | 1.62 | 20.83 | 25.95 | 11.21 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -2.43 | -5.44 | 8.48 | 28.67 | 22.01 | |||||
Net Income, 2 Yr. CAGR % | -2.43 | -5.44 | 8.48 | 28.67 | 22.01 | |||||
Normalized Net Income, 2 Yr. CAGR % | -7.69 | 0.05 | 22.72 | 31.32 | 11.85 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 2.88 | -0.96 | 9.84 | 29.17 | 22.76 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 40.67 | 3.11 | -32.6 | -36.48 | -6.74 | |||||
Accounts Receivable, 2 Yr. CAGR % | - | - | - | - | - | |||||
Total Assets, 2 Yr. CAGR % | 15.43 | 34.12 | 13.66 | 10.44 | 12.66 | |||||
Common Equity, 2 Yr. CAGR % | 12.81 | 15.84 | 18.92 | 26.6 | 23.16 | |||||
Tangible Book Value, 2 Yr. CAGR % | -12.91 | -14.43 | 16.32 | 44.2 | 28.57 | |||||
Cash From Operations, 2 Yr. CAGR % | 145.34 | 120.96 | -36.18 | -11.44 | -8.72 | |||||
Capital Expenditures, 2 Yr. CAGR % | 57.06 | 16.23 | 10.89 | 4.45 | 4.83 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 96.59 | 1.58K | -60.49 | 0.86 | 25.17 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 87.62 | 308.76 | -57.2 | 0.42 | 21.68 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | -1.87 | 14.15 | 23.93 | 21.56 | 13.22 | |||||
Gross Profit, 3 Yr. CAGR % | 2.51 | 2.94 | 17.26 | 19.26 | 13.03 | |||||
EBITDA, 3 Yr. CAGR % | 66.35 | -0.56 | 11.11 | 20.07 | 18.03 | |||||
EBITA, 3 Yr. CAGR % | 76.34 | -0.73 | 11.29 | 20.85 | 18.75 | |||||
EBIT, 3 Yr. CAGR % | 86.85 | -1.59 | 9.93 | 19.42 | 18.75 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 9.54 | -2.32 | 2.43 | 17.47 | 21.4 | |||||
Net Income, 3 Yr. CAGR % | 9.54 | -2.32 | 2.43 | 17.47 | 21.4 | |||||
Normalized Net Income, 3 Yr. CAGR % | 101.71 | -2.1 | 10.09 | 21.18 | 22.03 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 7.35 | 1.97 | 5.71 | 18.68 | 21.98 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 16.88 | 29.04 | -23.67 | -24.05 | -28.61 | |||||
Accounts Receivable, 3 Yr. CAGR % | - | - | - | - | - | |||||
Total Assets, 3 Yr. CAGR % | 4.01 | 19.5 | 21.97 | 16.04 | 8.58 | |||||
Common Equity, 3 Yr. CAGR % | 16.17 | 16.88 | 14.78 | 26.22 | 19.57 | |||||
Tangible Book Value, 3 Yr. CAGR % | 3.06 | -3.59 | -5.69 | 34.93 | 23.71 | |||||
Cash From Operations, 3 Yr. CAGR % | 32.96 | 88.97 | 21.22 | -4.33 | -32.77 | |||||
Capital Expenditures, 3 Yr. CAGR % | -4.89 | 36.92 | 16.88 | 4.32 | 9.1 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 136.39 | 17.29 | 372.25 | -25.71 | -15.65 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 163.93 | 15.66 | 90.56 | -24.56 | -14.22 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 6.3 | 9.65 | 9.85 | 12.71 | 19.1 | |||||
Gross Profit, 5 Yr. CAGR % | 7.95 | 7.85 | 10.6 | 7.58 | 14.23 | |||||
EBITDA, 5 Yr. CAGR % | 17.57 | 24.98 | 46.71 | 7.82 | 10.66 | |||||
EBITA, 5 Yr. CAGR % | 19.56 | 27.23 | 52.07 | 8.13 | 11.01 | |||||
EBIT, 5 Yr. CAGR % | 20.22 | 28.64 | 56.23 | 7.42 | 10.35 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 36.31 | 66.18 | 9.12 | 9.06 | 9.85 | |||||
Net Income, 5 Yr. CAGR % | 36.31 | 66.18 | 9.12 | 9.06 | 9.85 | |||||
Normalized Net Income, 5 Yr. CAGR % | 21.99 | 36.12 | 64.5 | 8.13 | 10.69 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 34.2 | 65 | 8.34 | 12.09 | 12.23 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 8.1 | 8.39 | -6.22 | -2.81 | -17.3 | |||||
Accounts Receivable, 5 Yr. CAGR % | - | - | - | - | - | |||||
Total Assets, 5 Yr. CAGR % | 7.71 | 10.39 | 7.77 | 15.79 | 18.16 | |||||
Common Equity, 5 Yr. CAGR % | 6.13 | 9.79 | 17.26 | 20.68 | 18.06 | |||||
Tangible Book Value, 5 Yr. CAGR % | 6.56 | 12.28 | 8.17 | 13.25 | 6.75 | |||||
Cash From Operations, 5 Yr. CAGR % | 10.93 | 25.78 | -0.78 | 39.55 | 8.21 | |||||
Capital Expenditures, 5 Yr. CAGR % | -10.93 | -15.24 | 1.14 | 22.87 | 11.9 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 74.11 | 4.11 | 15.43 | 9.5 | 177.01 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 72.31 | 4.9 | 27.33 | 8.47 | 58.96 |
- Stock Market
- Equities
- MOH Stock
- Financials Molina Healthcare, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















